

WED, APR 3 • 5:00 PM – 6:00 PM PT • COLUMBIA D (LEVEL 3)

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

Attend to hear about 21CTP.LEUK01, a phase II trial for patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Site selection starting soon!

YOU WILL ALSO LEARN ABOUT:

- What sites can expect:
 - Feasibility survey outreach and site selection
 - Site funding and contracts
 - CTP systems – EDC, IRB, eISF
- Three SWOG CTP trials in development

21CTP.GU01

Phase II platform trial in first-line muscle-invasive bladder cancer with multiple arms of neoadjuvant therapy defined by molecular subtype

21CTP.HN01

Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies

21CTP.BREAST01

Phase II platform trial using circulating tumor DNA to monitor treatment response in HR+, HER2- metastatic breast cancer

- Other SWOG CTP projects in the works
- The CTP process: from a joint SWOG Committee/Industry Partner "idea" to protocol activation

All are invited!

SWOG CLINICAL TRIALS PARTNERSHIPS

AN LLC OF THE HOPE FOUNDATION FOR CANCER RESEARCH

For more information, visit swogctp.org

Email us at CTP@swog.org

TROPION-Breast03

In another model, SWOG CTP provides scientific leadership and is lead academic group for this global AstraZeneca-sponsored registration trial. Over 40 SWOG sites selected and in process of activation or are enrolling.